Silicon Canals
TRENDING
  • Mobility
  • AI
  • FinTech
  • Software & SaaS
No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
No Result
View All Result
Silicon Canals
No Result
View All Result

London-based startup Causaly raises €4.3M in Series-A funding to accelerate its drug discovering AI

Akansha Srivastava by Akansha Srivastava
November 20, 2019
in News, (Crowd)funding, AI and chatbots, Health & Medtech, Software & SaaS, Startups
0
London-based startup Causaly raises €4.3M in Series-A funding to accelerate its drug discovering AI
75
SHARES
LinkedInTwitterWhatsAppFacebook

It’s no new news that Artificial Intelligence or AI is being used to further many advancements in various fields. One such area where AI is making waves is personal health and drug discovery. There are many companies that made headlines for employing AI to discover a breakthrough in medical sciences and you can now add another one to the list. The London-based AI startup Causaly has secured €4.3 million in Series A funding.  

The new funding round for the startup was lead by Pentech Ventures and EBRD Venture Capital. Existing investors such as Marathon Venture Capital and angel investors also participated in the funding round.

 - Partner content -
Cost of software - The Software house
The cost of building software
Marek Gajda, CTO of The Software House, shares his insights on building high-quality...Show More
Marek Gajda, CTO of The Software House, shares his insights on building high-quality software. Show Less
Read more

Reading through data at breakneck speeds

As per Causaly, over over 30 million biomedical articles have been published till now and about 100,000 new articles are being added every month. These published texts hold numerous insights. For example, correct drug development and treatment choices. However, making sense of it all and connecting the dots is time-consuming and inefficient for a human and therefore some key discoveries can be missed.

Causaly’s natural language processing AI reads and understands biomedical literature in a manner similar to humans. However, Causaly’s AI has read ‘everything’ ever written in biomedicine and is touted to visualise relevant relationships in seconds. Additionally, evidence-based decisions can quickly be supported by the system where previously time-consuming literature reviews took weeks or even months to perform.

Causaly’s use cases

Causaly is apparently working with several pharma and biotech companies, including Novartis, as well as with hospitals and academia. The company’s unique AI platform is currently employed by R&D and commercial functions to enable overall better decision-making based on evidence in areas such as Drug Discovery, Drug Safety, Clinical Trials, Epidemiology, Health Economics, Market Access, Pharmacovigilance and IP departments. To realise this, the startup has teamed up with leading publishers and content brokers such as Copyright Clearance Center, Wiley and Sage.

“At Causaly our aim is to help researchers, doctors and decision-makers from industry and academia find the pivotal insights that are currently hidden in millions of biomedical documents. We believe that Causaly can transform how people find, visualise and interpret knowledge, and contribute to solving the most difficult and systemic problems in biomedicine and human health”, says Yiannis Kiachopoulos, Causaly’s co-founder & CEO. 

Artur Saudabayev, co-founder & CTO of the company adds, “We have assembled a stellar team of engineers which tackles a number of unsolved problems in Natural Language Understanding including the goal of reaching and in certain aspects surpassing human reading performance for linguistic causality comprehension. This investment will help us to substantially grow our technology development and customer success teams.”

Main image picture credits: Casualy

Stay tuned to Silicon Canals for more European technology news.

close

Want to stay on top of the latest rounds, coolest tech and hottest startups?

Subscribe to our free, daily news blast and stay up-to-date!

Check your inbox or spam folder to confirm your subscription.

 - Partner content -
Nebula CTO Andre Witte
Cloud spend management 😱
Tracking cloud spend can be tricky. Learn from Nebula's CTO Andre Witte how to keep the...Show More
Tracking cloud spend can be tricky. Learn from Nebula's CTO Andre Witte how to keep the costs at bay in 2021. Show Less
Read more
Tags: AISaaS
Share5Tweet17SendShare35

Featured events

07apr10:0012:30FeaturedWorkshop: pr for startupsHow to grow your startup with the help of public relations

Partner content | Work with us

The Humblebrag launches online course to help emerging leaders amplify their visibility and voice

Blue Tulip Awards announce 5 finalists in the Food & Water and Education & Employment theme

Impact media foundation 5 Media offers grants up to €100,000 per year to drive a sustainable future

Here’s how cryptocurrency will take over the world

Blue Tulip Awards is driven by purpose: why innovation and equality go hand in hand

Breaking news from Amsterdam | Partner

Amsterdam-based Founda Health raises €12.3M to build infrastructure for global healthcare sector; here’s how

Combining financial with human capital in Amsterdam: Volta, LevelUp and Tech Rise on their approach

Here’s why Just Eat Takeaway is expanding its offices in Amsterdam

Amsterdam-based Veylinx uses Nobel Prize-winning approach to solve the problem of unreliable survey data; raises €1.6M

  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy policy
  • Terms & Conditions Silicon Canals

Silicon Canals 2014-2020 | Website: Bright Idiots

No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdam
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact

Silicon Canals 2014-2020 | Website: Bright Idiots

X

This website uses cookies to ensure the best possible experience. We may share this information with our advertising and analytics partners. By clicking 'Accept', you agree to our use of cookies and similar technologies. More info